How can I accelerate the development of my oncology drug candidate?

Quotient Sciences understands the challenges associated with developing oncology drugs. We offer the expertise to support biotech and pharmaceutical companies accelerate timelines. Get in touch with our experts today and find out more about how we can help.

Thank you for getting in touch.
If you have not heard from us in the next 48 hours, do not hesitate to call us on
UK +44 (0)115 974 9000 / US +1-800-769-3518

Get in touch with us today!

We respect your privacy. Find out how we handle your personal information in our privacy policy.

Accelerating your oncology program

Quotient Sciences understands the challenges associated with developing oncology drugs and has the expertise to successfully support biotech and pharmaceutical companies in accelerating development timelines from candidate selection through to commercial manufacture and supply.

Connect with us today to learn how we can help support the development and manufacturing needs of your oncology drug program.

Contact our experts

Supporting oncology drug development from candidate selection through to commercial manufacture and supply

In the past 5 years alone, Quotient has successfully worked on over 300 oncology development projects for 91 different oncology drug candidates spanning 34 different disease indications. Our extensive formulation expertise coupled with our agile and flexible approach to clinical and commercial manufacturing makes us the ideal partner to provide an end-to-end solution for the development of oncology drug products.

Our approach is simple

1. Pre-Formulation Assessment & Formulation Development

With unparalleled biopharmaceutics experience, we factor in and anticipate clinical considerations as well as the in vitro performance of pharmaceutical formulations. We emphasize the importance of data driven decisions in early development and prioritize the key API characterization data required. This allows our scientific experts to recommend selection of the appropriate API form as well as informing a data-driven strategy for preclinical and clinical pharmaceutical development based on the Developability Classification System (DCS). 

Early laboratory prototyping is performed on bench scale equipment, which mirror both small scale and mid to-large scale GMP manufacturing, in order to de-risk process scale-up and development should the molecule achieve its early clinical endpoints.

2. Clinical development: accelerating to POC

Our experts provide the full spectrum of manufacturing and supply paradigms, from traditional large batch manufacturing, through bright stock distribution and personalized manufacturing. There are compelling drivers for small batch sizes, such as conservation of API, and dose flexibility in order to meet individual subject needs and reduced stability needs. Fundamentally, with personalized manufacturing, the product is made on-demand, only when needed based on patient requirements. Overall, this alternative approach offers a reduction in waste and cost, while maximizing the potential for clinical success.

3. Formulation optimization and validation of product performance in humans

Formulation flexibility in healthy volunteer trials can be used to develop “patient ready” formulations for oncology molecules in less than half the time of the industry standard. This is accomplished by the close integration of real-time manufacturing and clinical testing, also known as Translational Pharmaceutics, which uses a 14-day “make-test” cycle, enabling formulation decisions to be made based on emerging human data.

4. Process development, “scale-up” & clinical manufacturing for Phase II/III

Recognizing the need to move rapidly through clinical development, we have the capability to efficiently scale-up drug product manufacturing processes from Phase I to meet the demands of later clinical trial requirements and ensure seamless transition to larger scale manufacturing and drug product commercialization.

5. Commercial manufacturing & supply

We work with our customers to configure a robust manufacturing and supply chain to meet their needs. Our investments in small-scale commercial equipment have allowed us to broaden the technologies and product formats available and ensure seamless continuity throughout the development life cycle. We can accelerate development programs through registration and process validation and our manufacturing facilities support batch sizes ranging from less than 1 kg to over 500 kg for solid oral dosage forms and up to 350 L for liquid formats.

Whether you are preparing for ANDA, NDA, MAA or Japanese NDA, we have the expertise to manufacture your registration and validation batches. Additionally, our experienced team has significant experience of supporting 505(b)(2) and all post-approval change filings.

Learn more

Access our resources

Get in touch
Our experts have insight into a variety of subjects. We are here to help.
Ask the Experts